301 related articles for article (PubMed ID: 31821370)
21. Baicalein resensitizes tamoxifen-resistant breast cancer cells by reducing aerobic glycolysis and reversing mitochondrial dysfunction via inhibition of hypoxia-inducible factor-1α.
Chen Y; Zhang J; Zhang M; Song Y; Zhang Y; Fan S; Ren S; Fu L; Zhang N; Hui H; Shen X
Clin Transl Med; 2021 Nov; 11(11):e577. PubMed ID: 34841716
[TBL] [Abstract][Full Text] [Related]
22. Sanguinarine combats hypoxia-induced activation of EphB4 and HIF-1α pathways in breast cancer.
Su Q; Wang J; Wu Q; Ullah A; Ghauri MA; Sarwar A; Chen L; Liu F; Zhang Y
Phytomedicine; 2021 Apr; 84():153503. PubMed ID: 33636580
[TBL] [Abstract][Full Text] [Related]
23. Comparative expression analysis of hypoxia-inducible factor-alpha and its natural occurring antisense in breast cancer tissues and adjacent noncancerous tissues.
Tasharrofi B; Soudyab M; Nikpayam E; Iranpour M; Mirfakhraie R; Sarrafzadeh S; Geranpayeh L; Azargashb E; Sayad A; Ghafouri-Fard S
Cell Biochem Funct; 2016 Dec; 34(8):572-578. PubMed ID: 27862063
[TBL] [Abstract][Full Text] [Related]
24. Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.
Alkner S; Ehinger A; Bendahl PO; Rydén L; Fernö M
Eur J Cancer; 2015 Nov; 51(16):2304-13. PubMed ID: 26243193
[TBL] [Abstract][Full Text] [Related]
25. Expression of LPA2 is associated with poor prognosis in human breast cancer and regulates HIF-1α expression and breast cancer cell growth.
Li M; Xiao D; Zhang J; Qu H; Yang Y; Yan Y; Liu X; Wang J; Liu L; Wang J; Duan X
Oncol Rep; 2016 Dec; 36(6):3479-3487. PubMed ID: 27805252
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
[TBL] [Abstract][Full Text] [Related]
27. GPER-mediated stabilization of HIF-1α contributes to upregulated aerobic glycolysis in tamoxifen-resistant cells.
Zhang Y; Song Y; Ren S; Zhang M; Zhang Z; Fan S; Liu X; Peng X; Qi Q; Shen X; Chen Y
Oncogene; 2023 Jan; 42(3):184-197. PubMed ID: 36400971
[TBL] [Abstract][Full Text] [Related]
28. GPER mediates the angiocrine actions induced by IGF1 through the HIF-1α/VEGF pathway in the breast tumor microenvironment.
De Francesco EM; Sims AH; Maggiolini M; Sotgia F; Lisanti MP; Clarke RB
Breast Cancer Res; 2017 Dec; 19(1):129. PubMed ID: 29212519
[TBL] [Abstract][Full Text] [Related]
29. Aberrant fatty acid profile and FFAR4 signaling confer endocrine resistance in breast cancer.
Chu X; Zhou Q; Xu Y; Jiang J; Li Q; Zhou Q; Wu Q; Jin M; Wang H; Gu Y; Wang X; Wang B; He S; He X; Wu C; Zhang F; Zhang Y
J Exp Clin Cancer Res; 2019 Feb; 38(1):100. PubMed ID: 30795784
[TBL] [Abstract][Full Text] [Related]
30. Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen.
Maraqa L; Cummings M; Peter MB; Shaaban AM; Horgan K; Hanby AM; Speirs V
Clin Cancer Res; 2008 Jan; 14(2):405-11. PubMed ID: 18223215
[TBL] [Abstract][Full Text] [Related]
31. The influence of tamoxifen treatment on the oestrogen receptor in metachronous contralateral breast cancer.
Kaas R; Peterse JL; Hart AA; Voogd AC; Rutgers EJ; van Leeuwen FE
Br J Cancer; 2003 Mar; 88(5):707-10. PubMed ID: 12618879
[TBL] [Abstract][Full Text] [Related]
32. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
33. Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer.
Helczynska K; Larsson AM; Holmquist Mengelbier L; Bridges E; Fredlund E; Borgquist S; Landberg G; Påhlman S; Jirström K
Cancer Res; 2008 Nov; 68(22):9212-20. PubMed ID: 19010893
[TBL] [Abstract][Full Text] [Related]
34. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer.
Love RR; Duc NB; Havighurst TC; Mohsin SK; Zhang Q; DeMets DL; Allred DC
J Clin Oncol; 2003 Feb; 21(3):453-7. PubMed ID: 12560434
[TBL] [Abstract][Full Text] [Related]
35. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
36. HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome.
Trastour C; Benizri E; Ettore F; Ramaioli A; Chamorey E; Pouysségur J; Berra E
Int J Cancer; 2007 Apr; 120(7):1451-8. PubMed ID: 17245699
[TBL] [Abstract][Full Text] [Related]
37. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
38. Expression of embryonal stem cell transcription factors in breast cancer: Oct4 as an indicator for poor clinical outcome and tamoxifen resistance.
Gwak JM; Kim M; Kim HJ; Jang MH; Park SY
Oncotarget; 2017 May; 8(22):36305-36318. PubMed ID: 28422735
[TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
Rydén L; Jirström K; Haglund M; Stål O; Fernö M
Breast Cancer Res Treat; 2010 Apr; 120(2):491-8. PubMed ID: 20135347
[TBL] [Abstract][Full Text] [Related]
40. Measuring IGF-1, ER-α and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer.
Chong K; Subramanian A; Sharma A; Mokbel K
Anticancer Res; 2011 Jan; 31(1):23-32. PubMed ID: 21273576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
